Biosimilars, complex generics and speciality would be key elements of Lupin strategy going forward, says Ramesh Swaminathan , CFO and ED, Lupin, in an interview with ET Now. Swaminathan says 2018-19 would be bad years for the pharma company and they expect things to become better only in 2019-2020. Read more here: For Lupin, uncertainties of 2018 would continue in 2019: Ramesh Swaminathan
Read More Here: For Lupin, uncertainties of 2018 would continue in 2019: Ramesh Swaminathan
No comments:
Post a Comment